Bpifrance Life Science Venture invests in Biotech and Medtech startups working on innovative therapeutic solutions or medical products that meet high unmet medical needs
Bpifrance Life Sciences Venture is active in venture capital across the entire life sciences sector. Through its funds, it invests in companies developing innovative therapeutic products or medical technologies that meet strong, unmet medical needs at an early-stage, mainly through Series A and B, with the capacity to support companies over the long term.
Among its funds, the Life Sciences Venture team can notably rely on InnoBio 2, an investment fund whose subscribers are Bpifrance, Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Fund of Investment and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative therapeutic products, close to or in early clinical development, with the objective of bringing them to clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
Bpifrance Le Hub serves as the operational partner for startups and scaleups backed by Bpifrance's venture capital innovation funds. It offers tailored support through a comprehensive framework based on five pillars: operational guidance, business development and partnerships, recruitment, peer-to-peer exchanges and professional club activities, as well as visibility and communication initiatives.
-
Localisation du HQ
Paris
-
Ticket cible
3 à 10M €
-
Durée d'investissement
5 à 7 ans
- Series A
- Series B
- Health
- Europe
- France
- Operating Partners
- Recrutement de talents
- Business Development
- Opportunité Réseau
- Communication / Relation Presse
- Partage entre pairs
